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Aims. To investigate the costs and cost-effectiveness of a short message service (SMS) intervention to prevent the onset of type 2
diabetes mellitus (T2DM) in subjects with impaired glucose tolerance (IGT).Methods. AMarkov model was developed to simulate
the cost and effectiveness outcomes of the SMS intervention and usual clinical practice from the health provider’s perspective. The
direct programme costs and the two-year SMS intervention costs were evaluated in subjects with IGT. All costs were expressed
in 2011 US dollars. The incremental cost-effectiveness ratio was calculated as cost per T2DM onset prevented, cost per life year
gained, and cost per quality adjusted life year (QALY) gained. Results. Within the two-year trial period, the net intervention cost
of the SMS group was $42.03 per subject. The SMS intervention managed to reduce 5.05% onset of diabetes, resulting in saving
$118.39 per subject over two years. In the lifetime model, the SMS intervention dominated the control by gaining an additional
0.071 QALY and saving $1020.35 per person.The SMS intervention remained dominant in all sensitivity analyses. Conclusions. The
SMS intervention for IGT subjects had the superiority of lower monetary cost and a considerable improvement in preventing or
delaying the T2DM onset. This trial is registered with ClinicalTrials.gov NCT01556880.
1. Introduction
Prevention of diabetesmellitus (DM) is becoming an increas-
ing urgent public health concern all over the world. It is
estimated that there are 382 million diabetic subjects by 2013
in the world, and the number will increase to 592 million
by 2035 [1]. The rising prevalence of DM and its devastating
complications [2] poses a huge threat to human health and
places enormous economic burden to the society [3, 4].
Studies indicated that prediabetes is a major factor leading to
diabetes [5], and people with prediabetes have increased risk
of cardiovascular disease (CVD) and mortality [6–8].
Given the potentially immerse disease burden caused by
prediabetes, it is impending to implement cost-effective inter-
ventions to delay diabetes among subjects with prediabetes
and even reverse the prediabetes status. Delivery of short
message service (SMS) is part of mobile-based interventions
that has bridged an effective communication channel to
endeavor behavioral change, enhance disease-specific knowl-
edge, and subsequently improve health outcomes in the field
of preventivemedicine and chronic disease self-management.
Over the past decade, self-management education or support
by mobile-based applications has been launched to target the
blood glucose and HbA1C levels control in patients with type
2 diabetes mellitus (T2DM) [9]. Mobile-based applications
are evident tomodify the individual behavior to quit smoking
[10], but they are rarely applied in diabetes prevention.
A randomized controlled trial was conducted recently to
evaluate the efficacy of the SMS intervention and it showed
encouraging results in reducing T2DM onset among patients
with impaired glucose tolerance (IGT) [11].
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Regarding the cost-effectiveness analyses for add-on
interventions conventionally applied to prediabetes, the pre-
diabetic screening [12] and lifestyle modification [13–16]
have been demonstrated to be highly cost-effective strategies
in comparison with usual clinical practice. To determine
whether a lifestyle modification is cost-effective, it depends
on how preventive the specific strategy is and how much it
costs. Although previous cost-effective strategies of lifestyle
intervention have different combinations of interventions,
they achieve cost-effectiveness outcomes by decreasing the
incidence of T2DM and its complications through slowing
the progression to T2DM and early detection of undiagnosed
abnormal glucose tolerance [16–19].
In view of the significant effectiveness of the SMS inter-
vention in preventing T2DM among prediabetes subjects and
its relative low cost, it is tempting to assume that the SMS
intervention is cost-effective. However, it is unethical and
infeasible to wait until perfect lifetime data are available to
validate the cost-effectiveness of any intervention. Decision
modelling is proved to be an effective method to conduct
economic evaluation of clinical interventions over lifetime.
This technique compares the intervention of interest with the
alternative options by incorporating all appropriate evidence
of costs and effectiveness, simulating disease paths over
longer time span, and reflecting uncertainty in evidence [20].
Using data from relevant epidemiological studies and
clinical trials, we constructed aMarkovmodel to compare the
strategy of delivering the SMS intervention programme as an
additional support to usual clinical practice and usual clinical
practice alone in managing subjects with IGT. Depending
upon the strategy applied, subjects in SMS intervention
group had lower T2DM onset rate compared to the usual
care, resulting in lower cost of managing T2DM and longer
life years, which might compensate the additional cost of
delivering the SMS intervention.
2. Method
2.1. Markov Model. A decision analytic model with a state-
transition Markov process [21] was developed to simulate
long-term effects of cost and clinical effectiveness of inter-
ventions in a cohort of prediabetes under twomain strategies,
which were (1) SMS intervention in addition to usual clinical
practice and (2) usual clinical practice. The TreeAge Pro 2013
software (TreeAge Software, Inc., Williamstown, MA, USA)
was used for the modelling. Long-term modelling referred
to time horizon over a 50-year period beyond the two-
year intervention. The natural history referred to previous
economic evaluation of diabetes prevention [15, 22–24]. The
one-year transition cycle moved from one health state to
another amongst four Markov states: normal glucose toler-
ance (NGT), IGT, T2DM, and death (Figure 1). An individual
had the likelihood to transit from current health state to a
different health state or remain in their current health state
at the end of one-year cycle in this Markov process [21].
Compared to the usual practice group, the SMS intervention
led to different transition probabilities among these four
disease states, resulting in extra cost in addition to usual
care. For patients who transit to diabetes were assumed to
Death
Normal glucose tolerance (NGT)
Impaired glucose tolerance (IGT)
Type 2 diabetes mellitus (T2DM)
Figure 1: Annual transition diagram of Markov model.
stop receiving SMS intervention, therefore, the management
of T2DM in these two groups was assumed to follow the
same routine clinical practice in primary care setting. In other
words, the costs and health effects of T2DMwere the same for
all subjects, regardless of which group they belonged to. An
annual discount rate of 3% was undertaken in both the cost
and health outcomes as per the Panel on Cost-Effectiveness
in Health and Medicine recommended [25].
2.2. Transition Probability. As shown in Table 2, the annual
transition probabilities between health states were taken from
several data sources, including epidemiological studies and
estimation from cost-effectiveness models. The annual tran-
sition probability from IGT to T2DM in the usual practice
group in the first three years was adopted from the results of
the placebo arm in Diabetes Prevention Program (DPP) [27],
whereas the Diabetes Prevention Program Outcome Study
(DPPOS) [28] provided this transition probability for the
fourth year onwards. Subjects with IGT had about double risk
for T2DM during the first three years compared to that in
the fourth year onwards [27, 28]. The effect of SMS on the
transition from IGT to T2DM was reflected in the relative
risk of T2DM onset for SMS intervention against control
groups, which was reported by a randomized control trial
(Clinical Trials Registry Number: NCT01556880) among a
sample of Chinese professional drivers with IGT [11, 29–
31]. We adopted the relative risks for complete case analysis
reported. This trial also reveals the drop-out rates of SMS
intervention during the first year and second year, whichwere
38.9% and 30.3%, respectively. The proportion of subjects
who regressed to normal glucose regulation was taken from
the Caro et al. study [22] which was used to derive the annual
transition probabilities from DPP. Subjects with diagnosed
T2DM would either stay in that state or be absorbed into the
death state in the next year. All-causemortality rates for NGT
were adopted from the Hong Kong Life Table 2011 [32]. The
relative risks of mortality in IGT and T2DM were 1.50 (95%
CI 1.10–2.00) and 2.30 (95%CI 1.60–3.20), respectively, which
were used to adjust the age-specific death rate for subjects
with IGT or T2DM [23]. The incidence and mortality rates
reported in literature were converted to annual transition
probabilities using mathematical formula [33]: 𝑝 = 1 −
exp(−𝑟𝑡), where 𝑝 is the transition probability, 𝑟 is the rate,
and 𝑡 is the unit of time. Although subjects with diabetic
complication had a higher risk ofmortality, ourmodel did not
differentiate different complications related to diabetes and
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therefore applied the average mortality of DM for all diabetic
subjects.
2.3. Costs. Costs were estimated from the perspective of
health service provider. No clinical health service was
deployed to routinely screen or treat patients with prediabetes
in Hong Kong, and thus there were no costs assigned to
patients with NGT or prediabetes in the usual practice
group. The cost of a SMS intervention was the sum of two
components: the delivery cost of a total of 66 text messages
package via online programme platform and the staff cost of
sending those text messages to each subject.The delivery cost
of textmessages per subject was $4.15 in first year and $0.92 in
second year, in total of $5.08, while the staff cost of sending
text messages was estimated as $36.95 based on an estimate
of 5 minutes for delivering one SMS online and a median
hourly wage of $6.72 in 2011 [26]. The total intervention cost
per subject was $42.03. All costs were calculated in 2011 Hong
Kong dollars and converted to US dollars at a pegged rate of
US$1 = HKD$7.8. The annual total medical costs attributed
to each patient with type 2 diabetes were $1492.05 in 2004
year price [3], and those costs incurred in the usual clinical
practice were inflated to $1,729.90 in 2011 using the medical
services price index taken from Hong Kong Census and
Statistics Department [26].Themedical costs associated with
diabetes management were assumed to be the same for all the
years in this state. All costs data are summarized in Table 1.
2.4. Utilities. To calculate the quality adjusted life years
(QALYs) accumulated in the lifetime model, we adopted the
utility scores for each health state from literature. We applied
the same utility scores for subjects with NGT and IGT. The
utility scores for NGT/IGT and T2DM were 0.76 and 0.72,
respectively [23].
2.5. Cost-Effectiveness Outcomes. The main outcomes of the
cost-effectiveness analysis in this study were the incremental
cost-effectiveness ratios (ICER), in terms of cost per event
(T2DM onset) prevented, cost per life year gained, and cost
per QALY gained. The SMS intervention dominated control
group if the control group was more expensive and less
effective.
2.6. Sensitivity Analysis. Sensitivity analysis was performed
to explore the uncertainty on the clinical and interventional
parameters of model. Sensitivity analysis for the ICER of the
SMS intervention compared with usual clinical practice was
conducted on the transition probabilities with ranges sug-
gested by previous literature and experts in family medicine
and endocrine (Table 2). In addition, annual discount rate
with limits bounded by 0% (undiscounted) and 5% was
included in the analysis. Threshold analysis was undertaken
to capture the threshold values of model interventional
parameters at which the 50-year cumulative costs of SMS
groupwere equivalent to those of control group. For instance,
threshold values of intervention costs guided decision mak-
ing on the level of intervention subsidy from the health
service provider.
3. Results
3.1. Base-Case Scenario. The base-case scenario was based
on the SMS intervention and T2DM costs from Table 1 and
previously reported clinical parameters values from Table 2.
Results of base-case scenario are shown inTable 3. During the
two-year SMS intervention, compared to the usual practice
group, each subject in SMS group costs $118.39 less and the
SMS group reduced 5.05% of T2DM onset. Over the 50-
year period of time horizon, the cumulative costs of the SMS
intervention group per subject were substantially lower than
the control group. Given the 0.063 life years and 0.071 QALYs
gained in SMS group, the SMS intervention was a less costly
butmore effective strategy than control group. As a result, the
SMS intervention was beneficial for effectiveness and cost-
saving comparedwith the usual clinical practice in both short
and long time horizons.
3.2. Sensitivity Analysis. Sensitivity analysis was performed
by varying clinical and interventional parameters to test the
robustness of model conclusion. Table 4 presents the results
of sensitivity analysis which assessed the model robustness
of base-case scenario. The determinant status of SMS group
stayed unchanged when we varied various key parameters
including SMS drop-out rates, annual transition probabilities
between health states, and discount rate. Increased drop-
out rate at first year from base-case value to 100% led
to the zero increment cost, remaining dominant. Despite
variation in drop-out rates, the SMS intervention dominated
control group. When the annual transition probability from
IGT to T2DM at the first year of SMS intervention was
increased from 3.53% to 11.57%, which is equal to that
in the control group, the SMS group still cost $76.21 less,
remaining dominant. The threshold analysis, as shown in
Table 5, indicated that SMS group reached the equivalent
amount of total costs of control groups when the first year
intervention cost was increased to $1,704.04 per person from
original cost of $34.38. When the first year intervention cost
was fixed at $34.38, to reach the same total cost as control
group, the SMS intervention cost in the second year should
have increased from $7.64 to $3,093.78.The annual transition
probability from IGT to T2DM in first year in SMS group had
to rise from 3.53% to 12.22% before the SMS group became
no cheaper than control group. Similarly, only if the annual
probability from IGT to T2DM in second year enrolled in
SMS increased to 22.60% or higher, three times as base-case
scenario, would their total medical cost be higher than the
subjects in control group.
4. Discussion
This study found that, compared to usual clinical practice
only, it was cost-saving to add the nonpharmacological SMS
intervention in both the short and long time horizon. Given
the high drop-out rate in the SMS group from the previous
study, we assumed that the SMS intervention was provided
only in the first two years. Within the two-year span, the
SMS intervention led to a reduction of 5.05% of diabetes
onset in comparison with the usual practice. Although it
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Table 1: Unit costs (US$, year 2011 values) for the SMS intervention.
Resource component Unit cost Reference
SMS intervention
First year
Delivery charges of SMS via online platform∗ $4.15 [11]
Staff wage for SMS delivery† $30.23 [26]
Second year
Delivery charges of SMS via online platform∗ $0.92 [11]
Staff wage for SMS delivery† $6.72 [26]
Annual cost of T2DM‡ $1,727.90 [3]
Note. ∗A total of 66 short text messages’ package is sent to each subject. †An estimate of 5 minutes was spent for each SMS delivery and in total 330 minutes
was used for each subject, assuming the median hourly wage of $6.72. ‡Annual cost in 2004 year price was inflated to 2011 year price using the medical services
price index taken from Hong Kong Census Department.
Table 2: Clinical parameter value in base-case scenario and range used in sensitivity analysis.
Parameter Base-case Sensitivity analysis Reference
Minimum Maximum
SMS intervention
Drop-out rate at year 1 38.89% 0% 100% [11]
Drop-out rate at year 2 30.30% 0% 100% [11]
Relative risk of T2DM at year 1 from IGT 0.34 0.10 1.00 [11]
Relative risk of T2DM at year 2 from IGT 0.60 0.10 1.00 [11]
Annual transition probability from IGT to NGT
At all years 16.20% 5% 25% [22]
Annual transition probability from NGT to IGT
At all years 16.30% 5% 25% [22]
Incidence rate (cases per 100 person-years) of T2DM from IGT
Control at years 1–3 11.0 9.8 12.3 [27]
Control at year 4+ 5.6 4.8 6.5 [28]
Relative risk of mortality
IGT 1.5 1.1 2 [23]
T2DM 2.3 1.6 3.2 [23]
Utility
NGT 0.76 NA [23]
IGT 0.76 NA [23]
T2DM 0.72 NA [23]
Discount rate 3% 0% 5% [25]
Note: NGT = normal glucose tolerance; IGT = impaired glucose tolerance; T2DM = type 2 diabetes mellitus; NA = not applicable.
Table 3: Results of base-case scenario.
Base-case scenario SMS Control Incremental
2-year period
Mean cost (in USD) accrued per patient 342.94 461.33 –118.39
T2DM onset 12.55% 17.60% –5.05%
Cost per T2DM onset prevented Dominance
50-year period
Mean cost (in USD) accrued per patient 12107.40 12958.17 –850.77
LYs per patient 19.24 19.08 0.063
QALYs per patient 14.248 14.177 0.071
Cost per LY gained Dominance
Cost per QALYs gained Dominance
Note: T2DM = type 2 diabetes; LYs = life years; QALY = quality adjusted life year.
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Table 4: Results of sensitivity analyses.
Parameters Base-case Range for sensitivityanalysis
Range for incremental
cost (USD)
Range for cost
per LYs gained
SMS drop-out rate at year 1 38.89% 0.00%–100.00% −1669.66 to 0.00 Dominance
SMS drop-out rate at year 2 30.30% 0.00%–100.00% −1131.28 to −765.21 Dominance
Annual transition probability
From IGT to T2DM, control at year 1–3 10.42% 9.34%–11.57% −950.73 to −761.82 Dominance
From IGT to T2DM, SMS at year 1 3.53% 0.93%–11.57% −1324.36 to −76.21 Dominance
From IGT to T2DM, SMS at year 2 6.25% 0.93%–11.57% −1352.05 to −688.20 Dominance
From IGT to NGT 16.20% 5.00%–25.00% − 922.28 to −1063.06 Dominance
From NGT to IGT 16.30% 5.00%–25.00% −1117.45 to −979.19 Dominance
RR of mortality in IGT 1.5 1.1–2.0 −1015.49 to −1026.04 Dominance
RR of mortality in T2DM 2.3 1.6–3.2 −1087.30 to −953.95 Dominance
Discount rate 3.00% 0.00%–5.00% −1450.41 to −836.95 Dominance
Note: NGT = normal glucose tolerance; IGT = impaired glucose tolerance; T2DM = type 2 diabetes mellitus; RR = relative risk.
Table 5:Threshold analysis of parameters at which the costs of SMS
intervention and control became equivalent over a 50-year period.
Parameters Base-case Threshold
SMS intervention cost at year 1 $34.38 $1,704.04
SMS intervention cost at year 2 $7.64 $3,093.78
Annual transition probability
From IGT to T2DM, SMS at year 1 3.53% 12.22%
From IGT to T2DM, SMS at year 2 6.25% 22.60%
Note: IGT = impaired glucose tolerance; T2DM = type 2 diabetes mellitus.
costs a total of $42.03 per subject to conduct the SMS
intervention for two years, the money saved by treating less
diabetic cases overcompensated the cost of SMS intervention.
As a result, the SMS group cost $118.39 less per subject
and prevented 5.05% of diabetes onset. When projecting
the effects of the discrepancy in DM onset between the
two groups to the lifetime span, we found that the SMS
intervention accrued more life years gained (incremental
effectiveness: 0.071 QALY) and less cost (incremental cost:
−$1,020.35) than the control group. The robustness of the
lifetime model was verified by sensitivity analysis through
varying the transition probabilities and drop-out within wide
ranges.The threshold analysis showed that onlywhen the cost
of SMS intervention climbed to about $2000 ormore to reach
the break-even point with the control group.
While the SMS intervention has been shown to be cost-
saving in prediabetic population, the ICER values were not
available as the incremental cost is negative. Using the empir-
ical DPP/DPPOS data [16], the 10-year cost-effectiveness
analysis estimated that metformin overwhelmed the control
group with direct medical cost of care, and the ICER for
lifestyle intervention compared to control group was $10,037
per QALYs gained. Complementary results were reported
in Australian study modelling from a third-party payer
perspective [23], indicating that the intensive lifestyle mod-
ification dominated the control group but the ICER for the
metformin versus control group was $10,142 in Australian
dollars per QALYs gained. Lifestyle interventions in IGT
were found cost-effective in other contexts as well, while
most of these studies also adopted the effectiveness data
from the DPP/DPPOS cohort [22, 34, 35]. Some studies on
the CEA of interventions in prediabetes have established
more sophisticated models, which involve development of
complications after subjects developed diabetes. These stud-
ies adopted the Framingham or UKPDS risk functions to
differentiate the risks of diabetic complications in long term
based on the changes of clinical parameters (i.e., HbA1c,
lipid profile, systolic blood pressure, etc.) observed in the
trials. The incremental effectiveness in these studies is more
prominent than the finding in our study that 0.14 to 0.50
life years were gained by lifestyle intervention compared
to no intervention over the lifetime [14, 18]. Although the
incremental life years and QALYs found in our model were
smaller, it is noteworthy that we made a rather conservative
estimation, as we assumed the two intervention groups have
the same utilities after they developed diabetes. Moreover,
we found that the SMS intervention is cost-saving over both
short term and long term,which is favouring results for policy
makers.
The main strength of this cost-effectiveness analysis
model was that the sources of interventional parameter were
the valid estimate reported in a randomized controlled trial.
Additionally, our model estimated the short-term as well as
long-term outcomes of cost-effectiveness. This is important
as the initial setup cost invested to SMS group was shortly
balanced out within two years, and the incremental cost
was proportionally magnified between the two groups over
a 50-year period. As the threshold analysis supported the
increased costs of SMS in first and second year, there is poten-
tial area to set the patients’ out-of-pocket charges of SMS
intervention implemented in health service. Subsidy given by
health service provider or government may be an alternative
approach to deal with financing of the SMS implementation.
Threshold analysis further offered cautionary advice on the
termination of SMS intervention when the annual transition
probabilities from IGT to T2DM in first and second year of
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SMS group exceeded 12.22% and 22.60%, respectively. The
scenarios implied that the SMS intervention was no longer
supported by the nature of cost-saving. The feasibility and
sustainability of SMS intervention are another concern due
to about one-third of drop-out rates in first and second year.
Owing to the high levels of drop-out, the effects of SMS
intervention on ICERwere considerably diluted. In a scenario
of 100% drop-out in second year participation as illustrated in
sensitivity analysis, the incremental cost ($765.21) of one-year
intervention was smaller than that in base-case scenario.
Several drawbacks were noted in this study. Firstly, the
effectiveness of SMS intervention was based on a RCT
in Hong Kong Chinese population, but some clinical and
epidemiological data were adopted from DPP and DPPOS,
which are the US population-based studies. Due to lack of
Hong Kong local data, we assumed that data from other
sources were applicable in our model. It is likely that there
may be substantial differences in the clinical and epidemio-
logical data between the Hong Kong and the US populations;
however, the values of these parameters were applied the
same in both SMS group and control group, which will not
affect the relative effectiveness in the model. Secondly, the
interventional parameters were derived from randomized
controlled trial on the pilot basis with 104 IGT subjects
participating. Although the intervention has been shown to
be effective in pilot data, the effect of SMS on the reduction
of T2DM onset over time may be diluted in population-
based setting. This study reflects the reasonable need for
undertaking the SMS intervention on mass population with
prediabetes. Thirdly, the model was built based on some
simplified assumptions. For example, annual cost of T2DM
was uniform regardless of gender, complication experienced,
and insulin treated. Given the more diabetic complications
experienced, direct medical costs associated with a T2DM
subject increased sharply [36]. Furthermore, the model did
not account for the health states representing the presence of
diabetic complications as no evidence available shows that the
SMS intervention in prediabetes has impacts on the incidence
of diabetic complications.
5. Conclusions
This cost-effectiveness analysis reveals that the SMS inter-
vention for subjects with prediabetes had the superiority of
lower cost and a considerable improvement in preventing
or delaying the T2DM onset. Encouraging efforts of clinical
and cost-effectiveness outcomes were diluted due to the
loss of participation over the 2-year intervention. This study
indicated that it was cost-saving to prevent T2DM through
implementing nonpharmacological SMS intervention among
prediabetics.
The Significant Findings of the Study
The SMS intervention was a low-cost and effective pro-
gramme for type 2 diabetes mellitus prevention in subjects
with impaired glucose tolerance, resulting in cost-saving to
health service provider regardless of 2-year trial and 50-year
lifetime periods.
What This Study Adds
This trial-based cost-effectiveness analysis showed that the
SMS may be an add-on intervention applied to impaired
glucose tolerance management in routine clinical practice in
primary care setting.
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